Orally Disintegrating Tablets

Published on: 

Podcast interview with Nick Johnson, Strategic Marketing Director for Modified Release Technologies at Catalent Pharma Solutions

Related Content:

Solid/Semi-Solid DosageManufacturingDosage FormsManufacturing, Solid Dosage DrugsManufacturing, Drug Products
Increasing mRNA Product Stability with Lyophilization
Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal
INTERPHEX 2024: Implementing Contamination Control Strategies in Cell and Gene Therapy Facilities